Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Daito Pharmaceutical Co., Ltd. ( (JP:4577) ).
Daito Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange, operates in the healthcare sector with a focus on pharmaceutical products and drug-related services. The company has repurchased 113,500 shares of its common stock on the Tokyo Stock Exchange between December 1 and December 31, 2025, for a total of ¥150.8 million, as part of a broader share buyback program authorized by its board on October 10, 2025. Under this ongoing program, which runs through May 22, 2026 and allows for repurchases of up to 1,000,000 shares or ¥1.5 billion, Daito Pharmaceutical has cumulatively bought back 371,600 shares for approximately ¥468.2 million as of December 31, 2025, signaling continued capital allocation to shareholder returns and potential enhancement of capital efficiency.
The most recent analyst rating on (JP:4577) stock is a Hold with a Yen1261.00 price target. To see the full list of analyst forecasts on Daito Pharmaceutical Co., Ltd. stock, see the JP:4577 Stock Forecast page.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange (securities code 4577), operating in the healthcare sector with a focus on drug development and related pharmaceutical products and services.
Average Trading Volume: 65,294
Technical Sentiment Signal: Buy
Current Market Cap: Yen40.8B
Learn more about 4577 stock on TipRanks’ Stock Analysis page.